14 results on '"Opio V"'
Search Results
2. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
- Author
-
Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, and Gisbert JP
- Subjects
Male ,Constriction, Pathologic ,Inflammatory bowel disease ,Gastroenterology ,Deprescriptions ,0302 clinical medicine ,Crohn Disease ,Recurrence ,Risk Factors ,Medicine ,Young adult ,Mesalamine ,Aged, 80 and over ,Incidence ,Incidence (epidemiology) ,Remission Induction ,Age Factors ,Middle Aged ,Antirheumatic Agents ,030220 oncology & carcinogenesis ,Retreatment ,Disease Progression ,Female ,030211 gastroenterology & hepatology ,Tumor necrosis factor alpha ,Adult ,medicine.medical_specialty ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Colon ,Young Adult ,03 medical and health sciences ,Ileum ,Internal medicine ,Humans ,Immunologic Factors ,Colitis ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Hepatology ,Tumor Necrosis Factor-alpha ,business.industry ,Proportional hazards model ,Adalimumab ,Retrospective cohort study ,Protective Factors ,Inflammatory Bowel Diseases ,medicine.disease ,Infliximab ,Discontinuation ,Methotrexate ,Colitis, Ulcerative ,business ,Follow-Up Studies - Abstract
OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included. RESULTS: A total of 1,055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn's disease and ulcerative colitis patients, respectively. In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year. The treatment with adalimumab vs. infliximab (hazard ratio (HR)=1.29; 95% confi dence interval (CI)= 1.01-1.66), elective discontinuation of anti-TNFs (HR=1.90; 95% CI= 1.07-3.37) or discontinuation because of adverse events (HR= 2.33; 95% CI= 1.27-2.02) vs. a top-down strategy, colonic localization (HR= 1.51; 95% CI= 1.13-2.02) vs. ileal, and stricturing behavior (HR= 1.5; 95% CI= 1.09-2.05) vs. inflammatory were associated with a higher risk of relapse in Crohn's disease patients, whereas treatment with immunomodulators after discontinuation (HR= 0.67; 95% CI= 0.51-0.87) and age (HR= 0.98; 95% CI= 0.97-0.99) were protective factors. None of the factors were predictive in ulcerative colitis patients. Retreatment of relapse with the same anti-TNF was effective (80% responded) and safe. CONCLUSIONS: The incidence rate of infl ammatory bowel disease relapse after anti-TNF discontinuation is relevant. Some predictive factors of relapse after anti-TNF withdrawal have been identifi ed. Retreatment with the same anti-TNF drug was effective and safe.
- Published
- 2017
3. EFICACIA Y SEGURIDAD DEL METOTREXATO EN LA ENFERMEDAD INFLAMATORIA INTESTINAL: EXPERIENCIA DEL GRUPO DE MADRID
- Author
-
González-Lama, Y., primary, Taxonera, C., additional, López-Sanromán, A., additional, Pérez-Calle, J.L., additional, Bermejo, F., additional, Pajares, R., additional, McNicholl, A.G., additional, Opio, V., additional, Mendoza, J.L., additional, López, P., additional, Algaba, A., additional, Estellés, J., additional, Barbero, A., additional, Mendoza, J., additional, Maté, J., additional, and Gisbert, J.P., additional
- Published
- 2009
- Full Text
- View/download PDF
4. P074 ACUTE PANCREATITIS IN INFLAMMATORY BOWEL DISEASE
- Author
-
Bermejo, F., primary, López-San Román, A., additional, Taxonera, C., additional, Gisbert, J.P., additional, Pérez-Calle, J.L., additional, Vera, M.I., additional, Marin, I., additional, Martin, M.D., additional, Opio, V., additional, Carneros, J.A., additional, Van Domselaar, M., additional, Mendoza, J.L., additional, Luna, M., additional, Lopez-Serrano, P., additional, and Algaba, A., additional
- Published
- 2008
- Full Text
- View/download PDF
5. Colonic Tuberculosis. An Unusual Endoscopic Diagnosis
- Author
-
Gómez-Rubio, M., primary, de Cuenca, B., additional, Opio, V., additional, Ulloa, J., additional, and Garcia, J., additional
- Published
- 1993
- Full Text
- View/download PDF
6. Colonic tuberculosis. An unusual endoscopic diagnosis.
- Author
-
G�mez-Rubio, M., de Cuenca, B., Opio, V., Ulloa, J., Garcia, J., and Gómez-Rubio, M
- Published
- 1993
- Full Text
- View/download PDF
7. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10 , 2885.
- Author
-
Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán MT, Rodríguez Mondéjar S, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero Ó, Irisarri R, Lluis L, Blázquez Gómez I, Zapata EM, José Alcalá M, Martínez Pascual C, Montealegre M, Mata L, Monrobel A, Hernández Camba A, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, Gisbert JP, and On Behalf Of The EpidemIBD Study Group Of Geteccu
- Abstract
The authors wish to make the following corrections to this paper [...].
- Published
- 2022
- Full Text
- View/download PDF
8. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.
- Author
-
Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán MT, Rodríguez Mondéjar S, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero Ó, Irisarri R, Lluis L, Blázquez Gómez I, Zapata EM, José Alcalá M, Martínez Pascual C, Montealegre M, Mata L, Monrobel A, Hernández Camba A, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, and Gisbert JP
- Abstract
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.
- Published
- 2021
- Full Text
- View/download PDF
9. Phase IV noninferiority controlled randomized trial to evaluate the impact on diagnostic thinking and patient management and the test-retest reproducibility of the Gaxilose test for hypolactasia diagnosis.
- Author
-
Monsalve-Hernando C, Crespo L, Ferreiro B, Martín V, Aldeguer X, Opio V, Fernández-Gil PL, Gaspar MJ, Romero E, Lara C, Santander C, Torrealba L, Savescu T, and Hermida C
- Subjects
- Adult, Aged, Decision Making, Disaccharides administration & dosage, Disaccharides adverse effects, Female, Humans, Hydrogen metabolism, Intention to Treat Analysis, Male, Middle Aged, Reproducibility of Results, Breath Tests methods, Disaccharides metabolism, Lactose Intolerance diagnosis, Xylose urine
- Abstract
Background: The diagnostic accuracy of the Gaxilose test (GT) for hypolactasia diagnosis has already been proved. The objectives of this clinical trial were to demonstrate the noninferiority of the GT compared to the hydrogen breath test (HBT) on the impact on diagnostic thinking and patient management, to evaluate the GT reproducibility with urine accumulated from 0 to 4 hours and from 0 to 5 hours and to assess test safety., Methods: We conducted a randomized, parallel, noninferiority clinical trial. Patients with clinical symptoms suggestive of lactose intolerance were screened for inclusion and randomly assigned to the GT arm or the HBT arm of the study. The impact on diagnostic thinking and patient management was analyzed with pretest and posttest questionnaires in which the investigators indicated their estimated probability of hypolactasia diagnosis and the intended management before and after the GT or the HBT (noninferiority margin: -10%). The primary outcome of the study was the impact on diagnostic thinking, expressed as the mean of the absolute values of the differences between the pretest and posttest probabilities of hypolactasia diagnosis. Patients randomized to the GT arm performed also the retest to evaluate the reproducibility of the GT., Results: A total of 147 patients were included in the intend-to-treat (ITT) population. Among them, 74 performed the HBT and 73 performed the GT. The results proved the noninferiority of the GT compared to the HBT on the impact on diagnostic thinking (ImpactGT = 31.74 ± 23.30%; ImpactHBT = 24.28 ± 19.87%; ΔGT-HBT = 7.46%; 95% confidence interval of ΔGT-HBT: 1.55%, infinite) and on patient management. The test-retest reproducibility was better for the GT with urine accumulated from 0 to 5 h: the intraclass correlation coefficient (ICC) was 0.5761, and the Kappa coefficient was 0.7548, indicative of substantial agreement between both tests. No serious adverse events were reported during the study., Conclusions: The GT has an impact on diagnostic thinking and patient management noninferior to that of the HBT, is reproducible and well tolerated. These results prove the clinical benefit of its use in the clinical practice (ClinicalTrials.gov identifier: NCT02636413).
- Published
- 2018
- Full Text
- View/download PDF
10. Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience.
- Author
-
González-Lama Y, Taxonera C, López-Sanromán A, Pérez-Calle JL, Bermejo F, Pajares R, McNicholl AG, Opio V, Mendoza JL, López P, Algaba A, Estelles J, Barbero A, Mendoza J, Maté J, and Gisbert JP
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Retrospective Studies, Spain, Treatment Outcome, Gastrointestinal Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Methotrexate therapeutic use
- Abstract
Background: Methotrexate is useful in inflammatory bowel disease (IBD), but its role is secondary because of its limited experience and a supposedly unfavorable safety profile., Aim: To describe the efficacy and safety of methotrexate in a long-term real clinical practice., Methods: Retrospectively reviewed records of IBD patients treated with methotrexate in eight hospitals of Madrid (Spain)., Results: A total of 77 patients were included (80% Crohn's disease); 94% received methotrexate because of steroid dependency. Overall, 82% of the patients initially responded (28% remission). Eighty-eight percent of the patients followed maintenance treatment for a mean of 17 (range: 1-108) months. Forty percent of the patients lost response at a mean of 57 weeks after starting methotrexate. No statistically significant differences were found in the response rates in terms of the disease type, route of administration, or the Montreal Classification category. The mean methotrexate cumulative dose was 1108 mg (range: 25-6480). The main adverse events included 10 cases of gastrointestinal symptoms, four of myelotoxicity, and 10 of abnormal liver function tests, and led to methotrexate withdrawal in four (5%) patients. Transient elastography, performed in 46 patients, detected six additional cases with significant fibrosis and normal liver function tests., Conclusion: Methotrexate is useful in inducing a response in IBD, although its efficacy decreases frequently through the follow-up. Although methotrexate seems safe in the long term, in addition to biochemical controls, a more accurate method to detect liver damage should be considered.
- Published
- 2012
- Full Text
- View/download PDF
11. Genital fistulas in female Crohn's disease patients.: clinical characteristics and response to therapy.
- Author
-
de la Poza G, López-Sanroman A, Taxonera C, Marín-Jimenez I, Gisbert JP, Bermejo F, Opio V, and Muriel A
- Subjects
- Adalimumab, Adolescent, Adult, Age Factors, Anti-Infective Agents therapeutic use, Anti-Inflammatory Agents therapeutic use, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Ciprofloxacin therapeutic use, Female, Fistula etiology, Humans, Infliximab, Intestinal Fistula diagnosis, Intestinal Fistula etiology, Intestinal Fistula therapy, Metronidazole therapeutic use, Purines therapeutic use, Rectal Fistula diagnosis, Rectal Fistula etiology, Rectal Fistula therapy, Rectovaginal Fistula diagnosis, Rectovaginal Fistula etiology, Rectovaginal Fistula therapy, Retrospective Studies, Smoking, Time Factors, Treatment Failure, Tumor Necrosis Factor-alpha antagonists & inhibitors, Vaginal Fistula diagnosis, Vaginal Fistula etiology, Vaginal Fistula therapy, Vulvar Diseases diagnosis, Vulvar Diseases etiology, Young Adult, Crohn Disease complications, Fistula diagnosis, Fistula therapy, Vulvar Diseases therapy
- Abstract
Background: Genital fistulas (GF) can arise in the course of Crohn's disease (CD), are difficult to manage and determine a significant alteration of the quality of life., Aims: To review the joint experience of the Inflammatory Bowel Disease Units in six University Hospitals in the management of GF in Crohn's disease on female patients., Results: A total of 47 patients with GF were identified, affecting 3.8% of women with CD treated in our centers. A 47.5% of patients were smokers. The median of time from the diagnosis of CD reached 102 months. According to anatomical type, GF were classified as rectovaginal (74.5%), anovaginal/anovulvar (21.3%) and enterovaginal (4.3%). Main symptoms were vaginal discharge of fecal material (55.3%), vaginal passage of gas (40.4%), or both. Fistulas were treated with antibiotics in 59.6% of patients, without any lasting success. Thiopurines were used in 80.9% of cases, with 13.2% of complete and 23.7% of partial responses. Anti TNF-alpha therapy was applied in 63.8%, with a 16.7% of complete and a 30% of partial responses (all responding patients received infliximab). Surgery was indicated in 38.3% of patients, with a 22% of complete responses after a first operation and 38.8% after reintervention. In all, definitive closure after one or more of these therapies was achieved in only 31.9% of cases., Conclusion: Genital fistulas are a significant problem in female Crohn's disease patients. Therapy is not well defined and only partially effective (one in three cases). Surgical therapy stands out as the most effective treatment., (Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
12. [Self-training in needle-knife sphincterotomy].
- Author
-
de la Morena EJ, Domínguez M, Lumbreras M, Opio V, Moyano E, and Garćia Alvarez J
- Subjects
- Clinical Competence statistics & numerical data, General Surgery statistics & numerical data, Humans, Postoperative Complications epidemiology, Retrospective Studies, Sphincterotomy, Endoscopic instrumentation, Sphincterotomy, Endoscopic statistics & numerical data, Treatment Outcome, General Surgery education, Sphincterotomy, Endoscopic methods
- Abstract
Aim: To analyze our experience in self-training in needle-knife sphincterotomy and to estimate the number of procedures necessary to reach competence in this technique., Method: Retrospective analysis of the first 60 needle-knife sphincterotomies performed, paying attention to success rates, the need for one or two attempts and the incidence and severity of early complications. The results were analyzed and divided into 2-year periods. The training period was subsequently determined using a qualitative method which combines the three above-mentioned criteria and sets competence level at 90%., Results: Of the 60 attempted needle-knife sphincterotomies (five in Billroth-II patients), 54 (90%) were completed. The procedure was required in 20% of all the sphincterotomies completed. Needle-knife sphincterotomy was completed at the first attempt in 39 (65%) patients and complications appeared in 13 (22%), three (5%) of which were serious but not fatal. Analysis of 2 year periods showed an almost 100% increase in the total number of needle-knife sphincterotomies completed and in those completed at the first attempt, as well as a reduction in the complication rate, which subsequently stabilized at below 15%. Forty needle-knife sphincterotomies were needed to reach competence level., Conclusion: Needle-knife sphincterotomy can be learned without training from an endoscopist with experience in this technique. Competence can be reached after 40 procedures. Nevertheless, we propose an alternative method to our own to achieve competence in less time and with fewer complications.
- Published
- 2000
13. [Dysfunction and manometry of Oddi's sphincter].
- Author
-
de la Morena EJ, Lumbreras M, Opio V, Moyano E, and García Alvarez J
- Subjects
- Common Bile Duct Diseases diagnosis, Common Bile Duct Diseases physiopathology, Humans, Manometry, Sphincter of Oddi physiopathology
- Published
- 2000
14. Chronic mesenteric ischemia: a cause of refractory duodenal ulcer.
- Author
-
Gómez-Rubio M, Opio V, Acín F, Guilleuma J, Moyano E, and García J
- Subjects
- Chronic Disease, Humans, Male, Middle Aged, Duodenal Ulcer etiology, Ischemia complications, Mesentery blood supply
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.